www.fdanews.com/articles/192981-strides-receives-approval-for-generic-of-vesicare
Strides Receives Approval for Generic of Vesicare
October 7, 2019
Strides Pharma received FDA approval for solifenacin succinate tablets, a generic version of Astellas’ Vesicare tablets, for treatment of overactive bladders.
Solifenacin succinate is an antispasmodic for treating overactive bladder with symptoms of urinary incontinence, urgency and frequency.
Strides has 36 pending ANDAs with the FDA. The agency previously approved 66 of its ANDAs, the company said.